Lifescience Global

Editor’s Choice : Role of Primary Tumour Resection and Addition of Bevacizumab to Chemotherapy in the Management of Advanced Colorectal Cancer with Inoperable Metastasis: A Retrospective Analysis

product-logo-jao 1340476205

Role of Primary Tumour Resection and Addition of Bevacizumab to Chemotherapy in the Management of Advanced Colorectal Cancer with Inoperable Metastasis: A Retrospective Analysis
Pages 209-217
Javier Garde Noguera,
Elena Evgenyeva, Mireia Gil Raga, Asunción Juárez Marroquí, Juan Manuel Gasent Blesa, Juan Laforga, Laia Bernet, Mónica Clemente Císcar, Carlos Camps Herrero and Antonio Llombart Cussac
DOI: http://dx.doi.org/10.6000/1927-7229.2013.02.04.3

Published: 31 October 2013


Abstract: Purpose:To analyze the impact of primary tumour resection on treatment outcomes in patients with advanced colorectal cancer (CRC) and inoperable metastases at diagnosis in combination with optimal systemic therapy.

Methods:A retrospective study was carried out in four hospitals in Valencia (Spain) including all consecutive patients diagnosed between 1/2009 and 12/2010 of advanced CRC with inoperable metastasis and treated with a fluoropyrimidine and oxaliplatin combination chemotherapy regimens with or without bevacizumab (B). Treatment outcomes were compared between patients undergoing or not primary tumour resection.

Results:A total of 112 patients met inclusion criteria: 62 patients underwent resection of the primary tumour (Group 1) and 50 were treated with exclusive chemotherapy (Group 2). Globally, patients in group 2 presented more disfavorable characteristics. Forty-five (72%) and 31 (62%) patients received chemotherapy with bevacizumab respectively. Overallresponse rate(ORR) were 67% in Group 1 and 56% in Group 2. There were no statistically significant differences between the two groups in progression free survival (PFS) (12 vs. 10 months; p =0.11) and overall survival (OS) (27 vs. 22 months; p 0.1). B regimens increased ORR (73% vs. 42%; p = 0.003) and PFS (12 vs. 11 months; p = 0.019) but not OS. Complications were higher in the group of patients without primary tumour resection, particularly when associated to B regimens.

Conclusions:Primary tumour resection offers no survival gain for patients with advanced CRC and inoperable metastases. Benefits of adding Bevacizumab to standard chemotherapy were similar in both groups, but it increases the risk of complications in non-resected patients.

Keywords: Primary Tumour Resection, Advanced Colorectal Cancer, Metastases, Survival, Bevacizumab.
Download Full Article
Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedIn

OUR STRENGTHS

♦  Worldwide readership
♦  High quality content
♦  Maximum visibility
♦  Efficient publishing
♦  Optional Open Access

Publish your Research

Survey

As an author what type of publishing model you prefer?

780
Open Access
493
Optional Open Access
338
Subscription based
5 Votes left

Nafa Urbach Iwan Fals Siti Badriah Aura Kasih acha septriasa artis bugil dewi persik julia perez duo srigala ayu ting ting isyana sarasvati olga syahputra dewi persik syahrini luna maya nikita willy mulan jameela superman is dead